San Diego, CA -- (SBWIRE) -- 08/05/2014 -- An investigation on behalf of investors of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) shares over potential securities laws violations by AcelRx Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced .

Investors who purchased shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) concerning whether a series of statements by AcelRx Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

AcelRx Pharmaceuticals Inc reported that its annual Total Revenue rose from $$2.39 million in 2012 to $29.50 million in 2013 and that its respective Net Loss declined from $33.36 million to $23.43 million. Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) grew from $3.01 per share in November 2012 to as high as $12.69 per share in early 2014.

Then on July 25, 2014, AcelRx Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter for the Company's new drug application (“NDA”) for Zalviso™ (sufentanil sublingual tablet system). The Company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA. AcelRx Pharmaceuticals said that the Complete Response Letter contains requests for additional information on the Zalviso System to ensure proper use of the device. AcelRx Pharmaceuticals said that additional bench testing will be required and human factors testing may be required to address certain items in the Complete Response Letter.

Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) dropped from as high as $11.38 per share during July 25, 2014, to as low as $6.11 per share on July 28, 2014,

On August 1, 2014, NASDAQ:ACRX shares closed at $6.89 per share.

Those who purchased shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com